%0 Journal Article %T Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option %A Ricciuti, Biagio %A Lamberti, Giuseppe %A Roila, Fausto %A Metro, Giulio %J Translational Lung Cancer Research %D 2019 %B 2019 %9 %! Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option %K %X Rearrangements of the anaplastic lymphoma kinase ( ALK ) gene occur in approximately 5% of non-small cell lung cancers (NSCLCs), in which they identify a distinct subtype of lung tumor that shows exquisite sensitivity to therapy with ALK tyrosine kinase-inhibitors (ALK-TKIs) (1). %U https://tlcr.amegroups.org/article/view/28867 %P S378-S382 %@ 2226-4477